Trestolone Enanthate
MENT E · MENT Enanthate
Half-life
5 days
Time to Peak
2 days
Steady State
~25 days
Bioavailability
100%
Dose Range
25–200 mg
Frequency
2x weekly
Overview
Long-acting trestolone ester. No pharmaceutical product exists — exclusively UGL. PK estimated entirely by enanthate ester analogy. Allows less frequent dosing than MENT acetate. Same parent compound and potency considerations. Harm reduction: Same as trestolone acetate. Longer ester means slower clearance — side effects take longer to resolve if compound is discontinued.
Mechanism of Action
7-alpha-methyl-19-nortestosterone with enanthate ester for extended release.
Dosing Information
| Route | Dose Range | Half-life | Tmax | Frequency |
|---|---|---|---|---|
| Intramuscular (IM) | 25–200 mg | 5 days | 2 days | 2x weekly, Weekly |
Storage & Handling
Room temperature — Oil-based injectable (UGL only).
Used in Regimens
Trestolone Enanthate is not currently part of any catalog regimen.
Data Sources
- ester analogy Enanthate ester analogy — based on enanthate class release kinetics
Related Tools
Track Trestolone Enanthate with Doseline
Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.
Join the waitlistDoseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.